



September 10, 2014

Mirati Therapeutics to Present at BioCentury's NewsMakers in the Biotech Industry Conference

SAN DIEGO, Sept. 10, 2014 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that the company will present a business overview and update at BioCentury's 21st Annual NewsMakers in the Biotech Industry Conference on Friday, September 26, 2014 at 10:30 a.m. Eastern Time in New York.

A live audio webcast of the presentation will be accessible on the Investors page of the Company's website at www.mirati.com. Replays of the presentation will be available at the same location for 60 days following the conference.

About Mirati Therapeutics

Mirati Therapeutics is a targeted oncology company developing an advanced pipeline of breakthrough medicines for precisely defined patient populations. Mirati's approach combines the three most important factors in oncology drug development - drug candidates with complementary and compelling targets, creative and agile clinical development, and a highly accomplished precision medicine leadership team. The Mirati team is using a proven blueprint for developing targeted oncology medicines to advance and maximize the value of its pipeline of drug candidates, including MGCD265 and MGCD516, which are orally bioavailable, multi-targeted kinase inhibitors with distinct target profiles, and mocetinostat, an orally bioavailable, spectrum-selective histone deacetylase inhibitor. More information is available at www.mirati.com.

Company Contact:

Mirati Therapeutics Inc.
Mark J. Gergen
Executive Vice President & COO
858-332-3410

Investor Relations and Media Relations:

Jason Spark
Canale Communications
619-849-6005
jason@canalecomm.com

SOURCE Mirati Therapeutics, Inc.

News Provided by Acquire Media